Moberg Pharma (Q3 Review): Nordic leadership goes international as Israel launches and Karo deliveries near - Redeye

Moberg Pharma (Q3 Review): Nordic leadership goes international as Israel launches and Karo deliveries near - Redeye

Moberg Pharma delivered a strong Q3 report, with sales up 44% YoY and well ahead of our forecast, as Terclara® continued to gain market share in Sweden and Norway. Israel was launched as the first market outside the Nordics, Karo deliveries remain on track for around year-end, and a new U.S. patent extends protection to 2041. We raise our 2026e estimates and lower 2027e on higher R&D costs, which together with a higher WACC leaves our Base case intact at SEK14. Moberg Pharma scores as ‘Attractively Priced’ on Redeye's Value Score, with a Fair value of SEK15.

Länk till analysen i sin helhet: https://www.redeye.se/research/1193024/moberg-pharma-q3-review-nordic-leadership-goes-international-as-israel-launches-and-karo-deliveries-near?utm_source=finwire&utm_medium=RSS